May 21, 2020 / 12:53 PM / 11 days ago

BRIEF-Kadmon Holdings Reports Positive Topline Results Of Pivotal Trial Of Belumosudil

May 21 (Reuters) - Kadmon Holdings Inc:

* KADMON HOLDINGS INC - ANNOUNCES POSITIVE TOPLINE RESULTS OF PIVOTAL TRIAL OF BELUMOSUDIL (KD025) IN CHRONIC GRAFT-VERSUS-HOST DISEASE

* KADMON HOLDINGS INC - ORRS OF 73% AND 74% WITH BELUMOSDUIL (KD025) 200 MG QD AND 200 MG BID, RESPECTIVELY

* KADMON HOLDINGS INC - PARTICIPATING IN FDA’S REAL-TIME ONCOLOGY REVIEW PILOT PROGRAM

* KADMON - BELUMOSUDIL ACHIEVED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT ORR OF 73% WITH 200 MG ONCE DAILY & 74% WITH 200 MG TWICE DAILY

* KADMON HOLDINGS INC - BELUMOSUDIL HAS BEEN WELL TOLERATED AND ADVERSE EVENTS HAVE BEEN CONSISTENT WITH THOSE EXPECTED IN THE PATIENT POPULATION.

* KADMON HOLDINGS INC - ON TRACK TO COMPLETE ITS NDA SUBMISSION FOR BELUMOSUDIL (KD025) IN THE FOURTH QUARTER OF 2020 Source text: (bit.ly/3gcCz2C) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below